Pub Date : 2026-01-01DOI: 10.1016/j.arbres.2025.07.005
Mireia Dalmases , Lídia López Escuredo , Concepción Ruiz , Marta Puig Dupré , Jennifer Garcia , Cristina Embid , Ignasi Español , Andrea Murru , Ivan David Benitez , Ramon Farré
{"title":"The Nocebo Effect on CPAP Side Effects in Patients With OSA","authors":"Mireia Dalmases , Lídia López Escuredo , Concepción Ruiz , Marta Puig Dupré , Jennifer Garcia , Cristina Embid , Ignasi Español , Andrea Murru , Ivan David Benitez , Ramon Farré","doi":"10.1016/j.arbres.2025.07.005","DOIUrl":"10.1016/j.arbres.2025.07.005","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 44-48"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.arbres.2025.07.007
Qingping Zhong , Binglin Lai
{"title":"Endobronchial Liposarcoma With Cough and Wheezing in a 56-Year-Old Female","authors":"Qingping Zhong , Binglin Lai","doi":"10.1016/j.arbres.2025.07.007","DOIUrl":"10.1016/j.arbres.2025.07.007","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 69-70"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.arbres.2025.07.008
Diego Agustín Rodríguez-Chiaradía , José Gregorio González-García , Karys Khilzi , Benjamin Brenner , José Luis Fernández-Reyes , Judith Catella , Andris Skride , Antonio López-Ruiz , Hanh My Bui , Manuel Monreal , the RIETE Investigators
{"title":"The Predictive Value of PaCO2 in Patients With Pulmonary Embolism: Data From RIETE Registry","authors":"Diego Agustín Rodríguez-Chiaradía , José Gregorio González-García , Karys Khilzi , Benjamin Brenner , José Luis Fernández-Reyes , Judith Catella , Andris Skride , Antonio López-Ruiz , Hanh My Bui , Manuel Monreal , the RIETE Investigators","doi":"10.1016/j.arbres.2025.07.008","DOIUrl":"10.1016/j.arbres.2025.07.008","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 53-56"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.arbres.2025.07.020
Christian Domingo , Astrid Crespo-Lessmann , Lorcan McGarvey
{"title":"A New Horizon for an Old Disease: Modern Strategies for Approaching Chronic Cough","authors":"Christian Domingo , Astrid Crespo-Lessmann , Lorcan McGarvey","doi":"10.1016/j.arbres.2025.07.020","DOIUrl":"10.1016/j.arbres.2025.07.020","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 7-9"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.arbres.2025.04.010
Raúl Moreno-Zabaleta , Manel Luján Torne , Javier Sayas Catalán , Pedro García Torres , Daniel López Padilla , Mar Mosteiro Añón , Sergi Martí Beltrán , Ascensión Hernando Sanz , Mónica González Martínez , Olga Mediano
The purpose of this document is to establish SEPAR's official position on the use of high-flow nasal cannula (HFNC) therapy in the home management of patients with chronic respiratory diseases. This position statement is deemed necessary considering current evidence regarding HFNC use in chronic respiratory conditions, with the objective of standardizing its application. This consensus was developed by a panel of experts comprising specialists with established expertise in chronic respiratory failure and high-flow nasal cannula therapy. The panel of experts stablished recommendations in COPD, bronchiectasis, interstitial lung diseases, palliative care, rehabilitation, and chronic treatment settings.
{"title":"SEPAR Position Paper on the Use of High Flow Nasal Cannula Therapy in the Home Setting","authors":"Raúl Moreno-Zabaleta , Manel Luján Torne , Javier Sayas Catalán , Pedro García Torres , Daniel López Padilla , Mar Mosteiro Añón , Sergi Martí Beltrán , Ascensión Hernando Sanz , Mónica González Martínez , Olga Mediano","doi":"10.1016/j.arbres.2025.04.010","DOIUrl":"10.1016/j.arbres.2025.04.010","url":null,"abstract":"<div><div>The purpose of this document is to establish SEPAR's official position on the use of high-flow nasal cannula (HFNC) therapy in the home management of patients with chronic respiratory diseases. This position statement is deemed necessary considering current evidence regarding HFNC use in chronic respiratory conditions, with the objective of standardizing its application. This consensus was developed by a panel of experts comprising specialists with established expertise in chronic respiratory failure and high-flow nasal cannula therapy. The panel of experts stablished recommendations in COPD, bronchiectasis, interstitial lung diseases, palliative care, rehabilitation, and chronic treatment settings.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 35-43"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.arbres.2025.05.004
Ciro Casanova , Enrique Gonzalez-Dávila , Juan P. de Torres , Carlos Cabrera , Borja G. Cosio , Denis E. O’Donnel , Cristina Martínez-Gonzalez , Ingrid Solanes , Antonia Fuster , Carolina Gotera , Alicia Marin , Carlos Amado , Marta Iscar , José M. Marin , José Alberto Neder , Nuria Feu , Joan B. Soriano , José Luis López-Campos , Miguel Divo , Germán Peces-Barba , Bartolomé R. Celli
Rationale
The lung diffusing capacity for carbon monoxide (DLco), a metric of gas transfer, provides physiological information distinct from spirometry. While DLco independently predicts mortality in COPD, its integration into the GOLD spirometric staging (% FEV1) to improve risk assessment, remains unexplored.
Objectives
To determine if DLco enhances the predictive power of GOLD spirometric classification for all-cause and respiratory mortality.
Methods
We followed 469 patients (mean age 64 years, 58% FEV1) with complete lung function tests in the Spanish multicenter CHAIN study for up to 10 years, with mortality as the main outcome. Patients were dichotomized based on DLco impairment (<50% cutoff). A Cox proportional hazard model evaluated the added value of DLco to GOLD FEV1 spirometric staging for all-cause and respiratory mortality. Validation of the results was conducted in the Kingston COPD Canadian cohort (N = 300 patients).
Results
Over time, 184 (39.2%) patients died, 84 (17.9%) from respiratory causes. Adjusted analyses showed DLco < 50% independently predicted all-cause [HR = 1.83 (95%CI 1.32–2.54, p < 0.001)] and respiratory [HR = 2.27 (95%CI 1.43–3.60, p < 0.001)] mortality. Incorporating DLco < 50% increased mortality risk compared to FEV1 alone, particularly in GOLD stages 3 and 4, where survival time decreased by 1.23 years (p = 0.002) and 1.25 years (p = 0.004) for all-cause and respiratory deaths, respectively. These findings were validated in the Canadian cohort.
Conclusions
Adding DLco to FEV1 enhances the prognostic accuracy of the GOLD spirometric severity classification, especially for patients in GOLD stages 3–4 at higher risk of adverse outcomes.
{"title":"Lung Diffusing Capacity Improves the Prognostic Validity of the GOLD Spirometric Staging in COPD","authors":"Ciro Casanova , Enrique Gonzalez-Dávila , Juan P. de Torres , Carlos Cabrera , Borja G. Cosio , Denis E. O’Donnel , Cristina Martínez-Gonzalez , Ingrid Solanes , Antonia Fuster , Carolina Gotera , Alicia Marin , Carlos Amado , Marta Iscar , José M. Marin , José Alberto Neder , Nuria Feu , Joan B. Soriano , José Luis López-Campos , Miguel Divo , Germán Peces-Barba , Bartolomé R. Celli","doi":"10.1016/j.arbres.2025.05.004","DOIUrl":"10.1016/j.arbres.2025.05.004","url":null,"abstract":"<div><h3>Rationale</h3><div><span><span><span><span>The lung diffusing capacity for </span>carbon monoxide (DLco), a metric of </span>gas transfer<span>, provides physiological information distinct from spirometry. While DLco independently predicts mortality in </span></span>COPD<span>, its integration into the GOLD spirometric staging (% FEV</span></span><sub>1</sub>) to improve risk assessment, remains unexplored.</div></div><div><h3>Objectives</h3><div>To determine if DLco enhances the predictive power of GOLD spirometric classification for all-cause and respiratory mortality.</div></div><div><h3>Methods</h3><div>We followed 469 patients (mean age 64 years, 58% FEV<sub>1</sub><span><span><span>) with complete lung function tests in the Spanish multicenter </span>CHAIN study for up to 10 years, with mortality as the main outcome. Patients were dichotomized based on DLco impairment (<50% cutoff). A Cox </span>proportional hazard model evaluated the added value of DLco to GOLD FEV</span><sub>1</sub><span> spirometric staging for all-cause and respiratory mortality. Validation of the results was conducted in the Kingston COPD Canadian cohort (</span><em>N</em> <!-->=<!--> <!-->300 patients).</div></div><div><h3>Results</h3><div>Over time, 184 (39.2%) patients died, 84 (17.9%) from respiratory causes. Adjusted analyses showed DLco<!--> <!--><<!--> <!-->50% independently predicted all-cause [HR<!--> <!-->=<!--> <!-->1.83 (95%CI 1.32–2.54, <em>p</em> <!--><<!--> <!-->0.001)] and respiratory [HR<!--> <!-->=<!--> <!-->2.27 (95%CI 1.43–3.60, <em>p</em> <!--><<!--> <!-->0.001)] mortality. Incorporating DLco<!--> <!--><<!--> <!-->50% increased mortality risk compared to FEV<sub>1</sub><span> alone, particularly in GOLD stages 3 and 4, where survival time decreased by 1.23 years (</span><em>p</em> <!-->=<!--> <!-->0.002) and 1.25 years (<em>p</em> <!-->=<!--> <!-->0.004) for all-cause and respiratory deaths, respectively. These findings were validated in the Canadian cohort.</div></div><div><h3>Conclusions</h3><div>Adding DLco to FEV<sub>1</sub><span> enhances the prognostic accuracy of the GOLD spirometric severity classification, especially for patients in GOLD stages 3–4 at higher risk of adverse outcomes.</span></div><div>ClinicalTrials.gov Identifier: <span><span>NCT01122758</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 20-27"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.arbres.2025.07.023
Alejandro Cruz-Utrilla , Daniel Toledo-Alfocea , Pilar Escribano-Subias
{"title":"A Possible Association Between Galcanezumab and Pulmonary Arterial Hypertension","authors":"Alejandro Cruz-Utrilla , Daniel Toledo-Alfocea , Pilar Escribano-Subias","doi":"10.1016/j.arbres.2025.07.023","DOIUrl":"10.1016/j.arbres.2025.07.023","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 1","pages":"Pages 62-63"},"PeriodicalIF":9.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号